B2M

Beta-2 Microglobulin

Q: What is the International Staging System for myeloma?

The ISS uses serum B2M and albumin to stage multiple myeloma into three prognostic groups. Stage I: B2M <3.5 mg/L and albumin ≥3.5 g/dL (best prognosis). Stage II: neither Stage I nor Stage III. Stage III: B2M ≥5.5 mg/L (worst prognosis). The Revised ISS (R-ISS) adds LDH and high-risk cytogenetics to further refine prognosis. These staging systems guide treatment decisions, including whether to consider more aggressive therapies or stem cell transplantation.

Q: Can kidney problems cause elevated B2M?

Yes. B2M is filtered by the kidneys and almost completely reabsorbed by proximal tubular cells. In chronic kidney disease, reduced glomerular filtration leads to B2M accumulation in the blood. In patients with multiple myeloma, renal impairment (which is common due to light chain nephropathy) can amplify B2M elevation beyond what the tumor burden alone would cause. When interpreting B2M, always consider renal function—a creatinine and GFR should be checked simultaneously.

Q: What is the difference between serum and urine B2M?

Serum B2M reflects the overall rate of cell turnover and is used as a tumor marker and prognostic indicator. Urine B2M reflects proximal tubular function—normally, nearly all filtered B2M is reabsorbed by the proximal tubule, so very little appears in urine. Elevated urine B2M indicates proximal tubular damage (from heavy metals, aminoglycosides, antiretrovirals like tenofovir, or Fanconi syndrome) and is used independently of serum B2M to assess kidney tubular integrity.

Other

What is Beta-2 Microglobulin?

Beta-2 microglobulin (B2M) is a small protein (11.8 kDa) that forms the light chain of the major histocompatibility complex class I (MHC-I) molecule, which is expressed on the surface of virtually all nucleated cells. MHC-I molecules present intracellular peptides to CD8+ cytotoxic T cells and are essential for immune surveillance. B2M is non-covalently associated with the MHC-I heavy chain; when the MHC-I complex turns over, B2M is shed into the blood and filtered by the kidneys, where it is almost completely reabsorbed and catabolized by proximal tubular cells.

Serum B2M levels reflect the rate of cell turnover, making it a valuable tumor marker for hematologic malignancies with high cell proliferation rates—particularly multiple myeloma and lymphoma. In multiple myeloma, B2M is incorporated into the International Staging System (ISS) and Revised ISS (R-ISS) as the primary prognostic biomarker, with higher levels indicating greater tumor burden and worse prognosis. B2M is also a marker of renal function, as impaired glomerular filtration reduces B2M clearance; this dual relationship with tumor burden and kidney function must be considered when interpreting results. In chronic lymphocytic leukemia, non-Hodgkin lymphoma, and some solid tumors, B2M provides additional prognostic information.

Why It Matters

B2M is one of the most important prognostic markers in multiple myeloma. The ISS stages myeloma primarily by B2M and albumin: Stage I (B2M <3.5 mg/L, albumin ≥3.5 g/dL) has a median survival of approximately 62 months, while Stage III (B2M ≥5.5 mg/L) has a median survival of approximately 29 months. Serial B2M monitoring helps track treatment response and detect relapse. Beyond myeloma, B2M is a prognostic marker in CLL, non-Hodgkin lymphoma, and Waldenstrom macroglobulinemia. Elevated urinary B2M is an early indicator of proximal tubular dysfunction (as in Fanconi syndrome, heavy metal nephrotoxicity, or antiretroviral drug toxicity), as it reflects impaired tubular reabsorption.

Normal Reference Ranges

Group	Range	Unit
Adults (serum)	0.7–1.8	mg/L
Adults ≥60 years (serum)	0.7–3.0	mg/L
Urine	<300	μg/L

Reference ranges may vary by laboratory. Always compare results to the ranges provided by your testing facility.

What High B2M Levels Mean

Common Causes

Multiple myeloma (correlates with tumor burden and stage)
Chronic lymphocytic leukemia (CLL)
Non-Hodgkin lymphoma
Waldenstrom macroglobulinemia
Chronic kidney disease (impaired clearance)
Autoimmune diseases (SLE, rheumatoid arthritis, Sjogren's)
Viral infections (HIV, CMV, EBV)
Amyloidosis (AL type)
Chronic inflammation
Solid tumors with high cell turnover

Possible Symptoms

Elevated B2M itself does not produce symptoms
In multiple myeloma: bone pain, fatigue, recurrent infections, anemia, renal insufficiency, hypercalcemia
In lymphoma: lymphadenopathy, night sweats, unexplained weight loss, fever
In CLL: lymphadenopathy, hepatosplenomegaly, fatigue

What to do: Elevated B2M in the context of suspected or known hematologic malignancy requires comprehensive evaluation. For multiple myeloma, use B2M with albumin for ISS staging; add LDH and cytogenetics for R-ISS staging. Ensure renal function is assessed (creatinine, GFR), as kidney impairment independently raises B2M. For lymphoma and CLL, incorporate B2M into prognostic models. Serial monitoring tracks treatment response—declining B2M suggests effective therapy. If elevated without known malignancy, evaluate for hematologic disease, autoimmune conditions, chronic infections, and renal function.

What Low B2M Levels Mean

Common Causes

Low B2M levels are uncommon and typically not clinically significant
May be seen in some patients with early-stage or well-controlled disease

Possible Symptoms

Low B2M does not cause symptoms

What to do: Low B2M is generally reassuring and requires no specific investigation. In the context of multiple myeloma or lymphoma, a low B2M is a favorable prognostic indicator. No follow-up action is needed for isolated low B2M.

When Is B2M Testing Recommended?

At diagnosis of multiple myeloma for staging (ISS/R-ISS)
For serial monitoring of multiple myeloma treatment response
As a prognostic marker in CLL and non-Hodgkin lymphoma
When evaluating proximal tubular dysfunction (urine B2M)
In the workup of monoclonal gammopathy of undetermined significance (MGUS) progression risk

Frequently Asked Questions

The ISS uses serum B2M and albumin to stage multiple myeloma into three prognostic groups. Stage I: B2M <3.5 mg/L and albumin ≥3.5 g/dL (best prognosis). Stage II: neither Stage I nor Stage III. Stage III: B2M ≥5.5 mg/L (worst prognosis). The Revised ISS (R-ISS) adds LDH and high-risk cytogenetics to further refine prognosis. These staging systems guide treatment decisions, including whether to consider more aggressive therapies or stem cell transplantation.

Yes. B2M is filtered by the kidneys and almost completely reabsorbed by proximal tubular cells. In chronic kidney disease, reduced glomerular filtration leads to B2M accumulation in the blood. In patients with multiple myeloma, renal impairment (which is common due to light chain nephropathy) can amplify B2M elevation beyond what the tumor burden alone would cause. When interpreting B2M, always consider renal function—a creatinine and GFR should be checked simultaneously.

Serum B2M reflects the overall rate of cell turnover and is used as a tumor marker and prognostic indicator. Urine B2M reflects proximal tubular function—normally, nearly all filtered B2M is reabsorbed by the proximal tubule, so very little appears in urine. Elevated urine B2M indicates proximal tubular damage (from heavy metals, aminoglycosides, antiretrovirals like tenofovir, or Fanconi syndrome) and is used independently of serum B2M to assess kidney tubular integrity.

Related Biomarkers

ALBAlbumin LDHLactate Dehydrogenase CrCreatinine

Want your B2M levels analyzed?

Upload your lab results for an instant AI-powered breakdown of all your biomarkers.

Upload Lab Results →

Medical Disclaimer: This information is for educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Reference ranges may vary between laboratories. Always consult your healthcare provider for interpretation of your specific test results.